CDKN1B
CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
Overview
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Lapatinib, Cisplatin and Fluorouracil. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.73, affected pathway 0.76, literature 0.99, genetic association 0.75, somatic mutation 0.90, animal model 0.54). IntOGen calls it a driver in 12 cohorts (1 activating, 11 loss-of-function), covering Invasive Breast Carcinoma, Hepatocellular Carcinoma, Plasma Cell Myeloma, Prostate Adenocarcinoma, Small Intestinal Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
- 1 · What it is
CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA.
- 3 · How drugs use it
No product in this corpus aims at CDKN1B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1785 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P46527 (protein name, function text, keywords and locations (REST API)); CIViC gene CDKN1B (2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000111276 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: prostate cancer 0.63, thyroid cancer 0.65, neuroendocrine neoplasm 0.62, acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.56, breast cancer 0.63 (GraphQL API, CC0)); IntOGen CDKN1B (driver in 12 cohorts (Act 1, LoF 11); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichiometry. Location: Nucleus; Cytoplasm; Endosome (UniProt). Locus 12p13.1 (HGNC).
- Thyroid cancer: Open Targets association 0.65 with thyroid cancer (MONDO_0002108)
- Prostate cancer: Open Targets association 0.63 with prostate cancer (MONDO_0008315); IntOGen driver in 4 cohorts (PRAD)
- Breast cancer: Open Targets association 0.63 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Neuroendocrine tumours: Open Targets association 0.62 with neuroendocrine neoplasm (MONDO_0019496)
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Multiple myeloma: IntOGen driver in 2 cohorts (PCM)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 11 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CDKN1B" OR ABSTRACT:"CDKN1B" OR TITLE:"cyclin dependent kinase inhibitor 1B" OR ABSTRACT:"cyclin dependent kinase inhibitor 1B" OR TITLE:"Cyclin-dependent kinase inhibitor 1B" OR ABSTRACT:"Cyclin-dependent kinase inhibitor 1B" OR TITLE:"KIP1" OR ABSTRACT:"KIP1" OR TITLE:"P27KIP1" OR ABSTRACT:"P27KIP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN1B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZFHX3
Shares Thyroid cancer, Hepatocellular carcinoma, Breast cancer (all types), IntOGen.
- TargetHRAS
Shares Thyroid cancer, Neuroendocrine tumours, Breast cancer (all types), CIViC.
- TargetEPHB2
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Prostate cancer.
- TargetEPHA7
Shares Thyroid cancer, Neuroendocrine tumours, Hepatocellular carcinoma, IntOGen.
- TargetEPHA3
Shares Thyroid cancer, Neuroendocrine tumours, Breast cancer (all types), IntOGen.
- TargetMAX
Shares Small intestine cancer (small bowel adenocarcinoma), Neuroendocrine tumours, Breast cancer (all types), IntOGen.
- TargetKIF5B
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Head and neck squamous cell carcinoma.
- TargetEP300
Shares Prostate cancer (KEGG map), Neuroendocrine tumours, CIViC, IntOGen.